Overview |
bsm-54407R |
UBE2N (1F6 ) Monoclonal Antibody |
WB |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
Recombinant protein within human Ube2N aa 1-150. |
Monoclonal |
1F6 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
Store at -20°C for 12 months. |
Target |
7334 |
P61088 |
Cytoplasm, Nucleus |
Ubiquitin-conjugating enzyme E2 N; Bendless-like ubiquitin-conjugating enzyme; E2 ubiquitin-conjugating enzyme N; Ubc13; UbcH13; Ubiquitin carrier protein N; Ubiquitin-protein ligase N; UBE2N; BLU |
The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the 'Lys-63'-linked poly-ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the 'Lys-63'-linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. |
Application Dilution |
WB |
1:300-5000 |